Skip to main content

Advertisement

SpringerLink
Log in

Abnormal hypermethylation and clinicopathological significance of FBLN1 gene in cutaneous melanoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Fibulin-1 (FBLN1) is involved in the progression of some types of cancer. However, the role of FBLN1 in cutaneous melanoma (CM) has not been examined. The purpose of this study was to understand the molecular mechanisms and clinical significance of FBLN1 inactivation in CM. The expression of FBLN1 mRNA in CM tissues and adjacent normal skin tissues was analyzed by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Methylation-specific polymerase chain reaction was performed to examine the methylation status of the FBLN1 gene promoter. Furthermore, the methylation status of FBLN1 was analyzed with the clinicopathological characteristics and overall survival. qRT-PCR showed FBLN1 mRNA levels in cancerous tissues to be significantly decreased compared with that in adjacent normal skin tissues. The rate of FBLN1 promoter methylation was significantly higher in CM tissues than in adjacent normal skin tissues (P < 0.001). Downregulation of FBLN1 was strongly correlated with promoter methylation (P = 0.021). Promoter hypermethylation of FBLN1 was significantly associated with tumor stage (P = 0.019). In addition, FBLN1 methylation status was associated with significantly shorter survival time and was an independent predictor of overall survival. In conclusion, our results indicated that FBLN1 is a novel candidate of tumor suppressor gene and that promoter hypermethylation of FBLN1 is associated with tumor progression in CM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Marks R. Epidemiology of melanoma. Clin Exp Dermatol. 2000;25:459–63.

    Article  CAS  PubMed  Google Scholar 

  2. Kobayashi N, Kostka G, Garbe JH, Keene DR, Bächinger HP, Hanisch FG, et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem. 2007;282:11805–16.

    Article  CAS  PubMed  Google Scholar 

  3. Pupa SM, Giuffré S, Castiglioni F, Bertola L, Cantú M, Bongarzone I, et al. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res. 2007;67:4271–7. doi:10.1158/0008-5472.CAN-06-4162.

    Article  CAS  PubMed  Google Scholar 

  4. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis. 2008;25:377–88.

    Article  CAS  PubMed  Google Scholar 

  5. Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, et al. Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene. 2002;21:1097–107. doi:10.1038/sj/onc/1205178.

    Article  CAS  PubMed  Google Scholar 

  6. Cheng YY, Jin H, Liu X, Siu JM, Wong YP, Ng EK, et al. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer. 2008;99:2083–7. doi:10.1038/sj.bjc.6604760.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, et al. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 2011;50:571–9. doi:10.1002/mc.20735.

    Article  CAS  PubMed  Google Scholar 

  8. Xiao W, Wang J, Li H, Guan W, Xia D, Yu G, et al. Fibulin-1 is down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression. J Urol. 2013;190:291–301. doi:10.1016/j.juro.2013.01.098.

    Article  CAS  PubMed  Google Scholar 

  9. Peng H, Long F, Wu Z, Chu Y, Li J, Kuai R, et al. Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression. Biomed Res Int. 2013;2013:181384. doi:10.1155/2013/181384.

    PubMed Central  PubMed  Google Scholar 

  10. Shin SH, Park SY, Kang GH. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis. Am J Pathol. 2013;182:1275–85. doi:10.1016/j.ajpath.2013.01.004.

    Article  CAS  PubMed  Google Scholar 

  11. Yoo TH, Ryu BK, Lee MG, Chi SG. CD81 is a candidate tumor suppressor gene in human gastric cancer. Cell Oncol (Dordr). 2013;36:141–53. doi:10.1007/s13402-012-0119-z.

    Article  CAS  Google Scholar 

  12. Zhong X, Zhu Y, Mao J, Zhang J, Zheng S. Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer. J Cancer Res Clin Oncol. 2013;139:485–90. doi:10.1007/s00432-012-1353-5.

    Article  CAS  PubMed  Google Scholar 

  13. Timpl R, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol. 2003;4:479–89. doi:10.1038/nrm1130.

    Article  CAS  PubMed  Google Scholar 

  14. Burstein HJ, Schwartz RS. Molecular origins of cancer. N Engl J Med. 2008;358:527. doi:10.1056/NEJMe0800065.

    Article  CAS  PubMed  Google Scholar 

  15. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–93. doi:10.1038/nrc1507.

    Article  CAS  PubMed  Google Scholar 

  16. Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer. 2008;7:81. doi:10.1186/1476-4598-7-81.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work was funded by research grants from the Shanghai Health Bureau (no. 20114211), China.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Plastic Surgery, Huashan Hospital, Fudan University, No. 12, Wulumuqi Zhong Rd., Shanghai, 200040, China

    Bao-Jin Wu, Zhao-Ping Zhou & Wei Ding

  2. Department of Plastic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China

    Wen-Peng Li

  3. Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, 200040, China

    Ying-Zhi Wu

  4. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China

    Zhong-Wen Zhou

  5. Fudan University Shanghai Cancer Center, Shanghai, 200032, China

    Rong-Qing Zhang

  6. Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China

    Qing-Feng Liu

  7. Department of Plastic Surgery, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Rd., Shanghai, 200003, China

    Hua Jiang

Authors
  1. Bao-Jin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhao-Ping Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wen-Peng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ying-Zhi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhong-Wen Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rong-Qing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qing-Feng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hua Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Bao-Jin Wu or Hua Jiang.

Additional information

Bao-Jin Wu, Zhao-Ping Zhou, and Wen-Peng Li contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, BJ., Zhou, ZP., Li, WP. et al. Abnormal hypermethylation and clinicopathological significance of FBLN1 gene in cutaneous melanoma. Tumor Biol. 35, 123–127 (2014). https://doi.org/10.1007/s13277-013-1015-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1015-5

Keywords

Search

Navigation